IMMU Immunicum AB

Immunicum tillkännager deltagande i flera kommande bransch- och investerarmöten i september och oktober

Immunicum tillkännager deltagande i flera kommande bransch- och investerarmöten i september och oktober

Pressmeddelande

27 augusti 2021

Immunicum tillkännager deltagande i flera kommande bransch- och investerarmöten i september och oktober



Immunicum AB (publ) meddelade idag att man kommer att delta på följande konferenser och investerarmöten till och med den 31 oktober.



• 6th CAR-TCR Summit, 30 augusti – 2 september, 2021

Alex Karlsson-Parra, Chief Scientific Officer på Immunicum, kommer att deltaga som expert i en workshop på it den 30 augusti 2021. Han kommer att presentera den potentiella användningen av Immunicums ilixadencel- och DCOne®-plattformar för att förbättra kvaliteten på T-celler för CAR-T och andra adoptiva T-cellsbaserade cancerterapier.



• Pareto Securities’ 12th Annual Healthcare Conference, 1-2 september, 2021

Erik Manting, CEO på Immunicum, kommer att ge en presentation.



• SACHS 21st Annual Biotech in Europe Forum, 7-8 oktober, 2021

Erik Manting, CEO på Immunicum, kommer att ge en presentation.



• ESGO 22nd European Congress on Gynaecological Oncology, 23-25 oktober, 2021

Immunicum deltar och kommer att presentera prekliniska data för vaccinkandidaten, DCP-001, vid äggstockscancer.



• Neoantigen Based Therapies Summit, October 26 – 28, 2021

Alex Karlsson-Parra, Chief Scientific Officer på Immunicum, kommer att presentera kombinationspotentialen för Immunicums ilixadencel- och DCOne®-plattformar i relation till cancer-neoantigenbaserade terapeutiska tillvägagångssätt.

 

FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA:

Erik Manting

Chief Executive Officer

Telephone:

E-mail:

INVESTOR RELATIONS

Kristina Windrup Olander

Spikinc AB

Telephone: 4

E-mail:

PRESSFRÅGOR

Sophia Hergenhan & Jacob Verghese

Trophic Communications

Telephone: 30

E-mail: 



OM IMMUNICUM AB (publ)

Immunicum tillämpar sin expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. Med kompletterande terapeutiska angreppssätt i klinisk Fas II-utveckling baserade på intratumoral immunaktivering och canceråterfallsvaccin (relapse vaccine) är bolagets mål att förbättra överlevnad och livskvaliteten för en stor grupp cancerpatienter. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm.

Bilaga



EN
27/08/2021

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 1 director

A director at Mendus AB bought 55,000 shares at 5.000SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

12/17/25 December 17, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch